Assetmark, Inc Immuno Gen, Inc. Transaction History

Assetmark, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.46 - $29.95 $15,076 - $36,239	1,210 Added 45.32%	3,880 $115,000
Q3 2023 Oct 27, 2023	BUY	$14.09 - $19.87 $1,352 - $1,907	96 Added 3.73%	2,670 $42,000
Q2 2023 Aug 11, 2023	BUY	$3.75 - $20.05 $9,652 - $51,608	2,574 New	2,574 $48,000
Q4 2019 Feb 11, 2020	SELL	$2.25 - $5.8 $380 - $980	-169 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$5.07 - $7.92 $856 - $1,338	169	169 $1,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.